Aloha Health Network, a leading AI/ML provider of innovative solutions for accelerating clinical trial recruitment, has announced the launch of its enhanced proprietary SaaS platform to accelerate patient pre-selection and recruitment in pharmaceutical and biotech clinical trials.

Aloha Health Network's new service leverages state-of-the-art NLP or Natural Language Processing Algorithms to identify and pre-screen potential clinical trial participants-- based on various structured and unstructured data-points such as EMR medical history, Labs including ‘Goldilocks Zone’ biomarker values, Radiological Imaging findings, ICD10 codes, Billing Data and a bevy of other key criteria, including unstructured physician notes. 

By streamlining the patient recruitment process, the service helps clinical trial sponsors and CROs save time and resources while improving the chances of finding the right patients for their studies. Aloha’s sophisticated algorithms churn out weighted, rank-ordered screened patient lists in order of ‘best fit’ for trial--Aloha also incentivizes DEI in screened patients by weighting heavier for underrepresented ethnic minorities, in addition to gender, in trials as per the recent FDA ‘must-have’ mandate. “The U.S. population has become increasingly diverse, and ensuring meaningful representation of racial and ethnic minorities in clinical trials for regulated medical products is fundamental to public health,” said FDA Commissioner Robert M. Califf, M.D.*

"We're thrilled to introduce this next-generation technology to the pharmaceutical industry," says Dr. Rob Wynden PhD, CEO of Aloha Health Network. "Our SaaS platform is designed to tackle one of the biggest pain-points facing clinical trial sponsors and CROs today - the need to find and recruit qualified patients quickly and efficiently. With our service, sponsors can accelerate the time-to-market for their products, bring new treatments to patients faster, and be cost-effective relative to existing manual screening paradigms by an order of magnitude. I can confidently state that Aloha HN screens patients 100X faster than manual EMR searches, and is around 1/10th  or lesser of the cost."

Dr. Wynden has a past pedigree of being the CTO for GoBalto Inc in the Clinical Trial Management Software space, which was successfully sold to Oracle in Fall 2018, prior to kickstarting Aloha in 2019. A bunch of the Data Scientist, Product and assorted expert talent from GoBalto accompanied him into Aloha, further nuancing and contemporizing the NLP engine over the subsequent years (https://www.oracle.com/corporate/pressrelease/oracle-buys-gobalto-101718.html)

“Patient recruitment is a major bottleneck in the clinical trial process, with up to 80% of studies failing to meet their recruitment targets on time, besides being quite expensive. By automating the pre-selection and screening process, Aloha Health Network's SaaS service can help reduce considerably the time and cost of patient recruitment- while increasing significantly the likelihood of success.” says Dr. Singh MD, the Chief Medical Advisor for Aloha HN. Dr. Singh leverages his clinical acumen and C-Suite executive experience from various other pharmaceutical and biotech firms in order to further nuance and refine Aloha’s bioinformatics platform. 

In terms of sponsors assisted, Aloha HN has a proven pedigree of helping firms such as Boston Scientific Swing Therapeutics, Neuralace Therapeutics, besides others, with accelerating trial recruitment for various therapeutic indications, dramatically shaving timelines and shrinking costs for these firms.

Regarding HIPAA and GDPR compliance, each unique clinical ontological profile or phenotype created is anonymized as John Doe or Jill Doe, for instance, thus being devoid of Patient Identifiable Information (PII) - hence addressing any potential concerns.

The enhanced UI includes automated patient outreach tools, screening questionnaires and permission forms, and has features such as tailored, comprehensive,intuitive dashboards for Investigators and CRCs, as well as sponsors and CROs to track enrollment status.

The new service is part of Aloha Health Network's broader mission to transform clinical trial recruitment through innovative technology solutions. The company offers a suite of tools and services designed to help sponsors and CROs optimize patient recruitment and retention.

Aloha Health Network's service integrates seamlessly with existing clinical trial management systems and electronic health record systems while being fully HIPAA compliant. The platform also features advanced analytics and reporting capabilities, enabling sponsors and CROs to track recruitment metrics and performance in real-time via intuitive and seamless dashboards. "We believe that our SaaS platform has the potential to revolutionize the clinical trial recruitment landscape," says Wynden. "By automating and streamlining the patient pre-selection and recruitment process, we can help sponsors and CROs bring new treatments to market faster and more efficiently than ever before."

For more information about Aloha Health Network's SaaS platform for patient pre-selection and recruitment, visit www.alohahealth.net. 

References: 1. https://www.fda.gov/news-events/press-announcements/fda-takes-important-steps-increase-racial-and-ethnic-diversity-clinical-trials

2. https://www.oracle.com/corporate/pressrelease/oracle-buys-gobalto-101718.html